好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Persistently Impaired Antibody Response of Ocrelizumab-treated Multiple Sclerosis Patients to Third (“Booster”) mRNA Vaccine Against SARS-CoV-2
Multiple Sclerosis
P14 - Poster Session 14 (11:45 AM-12:45 PM)
12-005
To report antibody responses of ocrelizumab-treated MS patients following the third dose of mRNA vaccine against SARS-CoV-2 (mRNA-3rd vaccine).
In August 2021, third dose of mRNA vaccine against SARS-CoV-2 received emergency use authorization by the FDA for solid organ transplant recipients and similarly immunosuppressed patients, such as those treated with ocrelizumab. In contrast to transplant recipients, immune responses to third vaccine dose in MS population have not been evaluated to date.
This retrospective observational study includes 20 patients with relapsing MS (11 female, 9 male), 28-74 years of age (48.4 +/- 11.9), who were treated with ocrelizumab and underwent testing for antibodies to SARS-CoV-2 spike protein receptor-binding domain (anti-RBD) using Roche Elecsys platform before and after mRNA-3rd vaccine (BNT162b2/Pfizer n=12, mRNA-1273/Moderna n=8).

One patient, who had confirmed symptomatic COVID-19 between the second and third vaccine, had detectable anti-RBD titers prior to mRNA-3rd vaccine, that increased 9.5-fold following the third vaccine. The remaining 19 patients were seronegative 51.5+/- 55.9 days prior to mRNA-3rd vaccine. Of these, only two patients developed detectable anti-RBD 25.9+/-10.5 days after mRNA-3rd vaccine. Both of these patients had long intervals between ocrelizumab infusions and their first (226, 229 days) and third (136, 178 days) vaccines. However, other patients with similar long intervals did not develop detectable antibody titers, and in a logistic regression analysis the time to third vaccine dose was not unequivocally associated with seroconversion (OR=1.011 p=0.43).
Similarly to the reported poor antibody response to primary vaccination series, ocrelizumab-treated patients rarely developed anti-RBD titers even after the third mRNA vaccine against SARS-CoV-2. 
Authors/Disclosures
Pavle Repovic, MD, PhD (Multiple Sclerosis Center)
PRESENTER 		Dr. Repovic has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Repovic has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Repovic has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. Dr. Repovic has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion. Dr. Repovic has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. Dr. Repovic has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for BristolMyersSquibb. Dr. Repovic has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Genentech. Dr. Repovic has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for TG therapeutics. The institution of Dr. Repovic has received research support from Genentech. The institution of Dr. Repovic has received research support from Biogen.